Novel Interventions in HIV-1 Infection (IMIRC1003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01130376

Recruitment Status
:
Terminated
(Data from the 12 patients recruited has now been analysed, and it has been determined that it is sufficient to meet the study objectives.)

For several years there has been interest in why some people with HIV-1 progress more slowly to disease and have longer survival without Highly Active Antiretroviral Therapy (HAART) than others. The investigators and others have identified a few HIV positive individuals who can control their viral load for many years without HAART, these rare individuals do not lose their HIV-1-specific cellular immune responses, which are very important for controlling viral load. This group is referred to as long-term non-progressors (LTNP). Unlike LTNP the majority of HIV-1 infected individuals are chronic progressors (CP) who do not make effective HIV-1-specific cellular immune responses, even when on HAART. We propose to use a novel DNA vaccine boosted with immune based therapy (cytokines and hormones) to try to regenerate the missing HIV-1-specific cellular immune responses to make chronically infected HIV-1+ persons more like LTNP.

By injecting this novel DNA vaccine and immune based therapy into the people who are already infected with HIV-1, the immune system may be stimulated to mount a greater immune response not only to the vaccines but also to real HIV-1 particles and HIV-1-infected cells.

This will be a randomised, Phase I, open label comparative study running for 52 weeks (2 screen visits 2 weeks apart followed by 48 weeks of study). 50 patients will be screened in the initial phase of which 30 clade B infected individuals will be randomised into the study, which will consist of 3 arms:

Arm 1 will ascertain vaccine safety and toxicity in the presence of cytokine/hormone therapy.

Arm 2 will identify vaccine safety and toxicity.

Arm 3 will indicate safety and toxicity of cytokine/hormone therapy.

The target patients are chronically HIV-1 clade B infected persons who will have had a nadir CD4 T-cell count of >200 cells/ul blood before they started ART. The current CD4 T-cell count should be >400 cells/ul blood. Patients may have received ART for any length of time, but currently should be receiving NNRTI or boosted-PI based HAART, and have a viral load below the level of detection (50 copies/ml plasma). Patients will be bled on two occasions before commencing IBT regimens, in order to establish baselines, and then at regular intervals thereafter (weeks 0,1,2,4,6,8,12,16,24 and 48).

The treatment regimens are consistent with previous findings in animal models which suggest that administration of IL−2 during the antigen−specific T−cell contraction phase of an immune response (between 8 and 15 days post−vaccination) may preserve and lengthen clinically relevant responses. Furthermore studies in man have demonstrated that IL−2 administered before immunisation in ART−treated HIV−1−infected patients does not increase specific lymphoproliferation of T cells.

Recent preliminary studies in HIV−1−infected individuals using tetanus vaccines the investigators have shown that IL−2 administered after immunisation may be more effective at inducing sustained tetanus−specific responses than IL−2 administered before immunisation or together with immunisation. The dosages used in this study are based on those used in previous pilot studies of the administration of IL-2 + GM-CSF and rhGH and at these levels the drugs have been shown to have both positive effect on the immune response and demonstrated clinical benefit whilst being at a level which is safe and well tolerated in HIV-1 positive individuals. The dosage of the vaccine was based on a previous study where a dosage of this level has been shown to induce an immune response although this response was transient. In summary the investigators aim to increase the survival of vaccine responses through the administration of cytokines/hormones and boost memory responses with further rounds of immunisation.

The primary outcome will be analysis of safety and toxicity data in relation to grade 3 or above laboratory or clinical serious adverse event (SAE) which can be attributed to the treatments given [ Time Frame: Weekly ]

Secondary Outcome Measures
:

The secondary immunological outcomes will be percentage change from baseline to study time point in defined cellular immune responses. [ Time Frame: weekly ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Documented HIV-1 positive result.

Stable on HAART.

Two screening viral loads of <50 cps/ml on 2 consecutive occasions at least one month apart.

CD4 T cell count of >400 cells/ul.

Nadir CD4 T cell count of >200 cells/ul.

Over 18 years of age.

Willing and able to provide informed consent.

Female subjects must not be pregnant or lactating.

Subjects must be using adequate double barrier method of contraception as appropriate.

Exclusion Criteria:

Prior therapeutic vaccination.

Acute illness within 2 weeks of the start of the study.

Prior immunomodulatory therapy (e.g. IL-2, rhGH, GCSF, GM-CSF, HU)

Receiving immunosuppressive medication (e.g. Steroids)

Participation in other vaccine trials currently

Patients with diabetes mellitus type 2

Patients with cardiac abnormalities

Patients with pre-existing autoimmune disease

Patients with active neoplasia

Patients with evidence of any progression or recurrence of an underlying intra-cranial lesion